DIPG in Children - What Can We Learn from the Past?

Magimairajan Issai Vanan, David D Eisenstat, Magimairajan Issai Vanan, David D Eisenstat

Abstract

Brainstem tumors represent 10-15% of pediatric central nervous system tumors and diffuse intrinsic pontine glioma (DIPG) is the most common brainstem tumor of childhood. DIPG is almost uniformly fatal and is the leading cause of brain tumor-related death in children. To date, radiation therapy (RT) is the only form of treatment that offers a transient benefit in DIPG. Chemotherapeutic strategies including multi-agent neoadjuvant chemotherapy, concurrent chemotherapy with RT, and adjuvant chemotherapy have not provided any survival advantage. To overcome the restrictive ability of the intact blood-brain barrier (BBB) in DIPG, several alternative drug delivery strategies have been proposed but have met with minimal success. Targeted therapies either alone or in combination with RT have also not improved survival. Five decades of unsuccessful therapies coupled with recent advances in the genetics and biology of DIPG have taught us several important lessons (1). DIPG is a heterogeneous group of tumors that are biologically distinct from other pediatric and adult high grade gliomas (HGG). Adapting chemotherapy and targeted therapies that are used in pediatric or adult HGG for the treatment of DIPG should be abandoned (2). Biopsy of DIPG is relatively safe and informative and should be considered in the context of multicenter clinical trials (3). DIPG probably represents a whole brain disease so regular neuraxis imaging is important at diagnosis and during therapy (4). BBB permeability is of major concern in DIPG and overcoming this barrier may ensure that drugs reach the tumor (5). Recent development of DIPG tumor models should help us accurately identify and validate therapeutic targets and small molecule inhibitors in the treatment of this deadly tumor.

Keywords: blood–brain barrier; brain tumor; diffuse intrinsic pontine glioma; pediatric neuro-oncology; re-irradiation.

References

    1. Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL, et al. CBTRUS statistical report: ALSF infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol (2015) 17(Suppl 1):v1–35.10.1093/neuonc/nou327
    1. Epstein F. A staging system for brainstem gliomas. Cancer (1985) 56:1804–6.
    1. Recinos PF, Sciubba DM, Jallo GI. Brainstem tumors: where are we today? Pediatr Neurosurg (2007) 43:192–201.10.1159/000098831
    1. Choux M, Lena G, Do L. Brainstem tumors. In: Choux M, Di Rocco C, Hockley A, editors. Pediatric Neurosurgery. New York, NY: Churchill Livingstone; (2000). p. 471–91.
    1. Albright A, Packer R, Zimmerman R, Rorke L, Boyett J, Hammond G. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brainstem gliomas: a report from the children’s cancer group. Neurosurgery (1993) 33:1026–9.10.1227/00006123-199312000-00010
    1. Cartmill M, Punt J. Diffuse brain stem glioma. A review of stereotactic biopsies. Childs Nerv Syst (1999) 15:235–7.10.1007/s003810050379
    1. Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, Geoerger B, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg (2007) 107(1 Suppl):1–4.
    1. Cage TA, Samagh SP, Mueller S, Nicolaides T, Haas-Kogan D, Prados M, et al. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst (2013) 29:1313–9.10.1007/s00381-013-2101-0
    1. Wang ZJ, Rao L, Bhambhani K, Miller K, Poulik J, Altinok D, et al. Diffuse intrinsic pontine glioma biopsy: a single institution experience. Pediatr Blood Cancer (2015) 62:163–5.10.1002/pbc.25224
    1. Pirotte B, Lubansu A, Massager N, Wikler D, Goldman S, Levivier M. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg (2007) 107:392–9.10.3171/PED-07/11/392
    1. Chen X, Weigel D, Ganslandt O, Buchfelder M, Nimsky C. Diffusion tensor imaging and white mater tractography in patients with brainstem lesions. Acta Neurochir (2007) 149:1117–31.10.1007/s00701-007-1282-2
    1. Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of pediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol (2014) 128:573–81.10.1007/s00401-014-1319-6
    1. Puget S, Blauwblomme T, Grill J. Is biopsy safe in children with newly diagnosed diffuse intrinsic pontine glioma? Am Soc Clin Oncol Educ Book (2012) 32:629–33.10.14694/EdBook_AM.2012.32.629
    1. Corti M, Trione N, Risso D, Soto I, Villafañe MF, Yampolsky C, et al. Disseminated paracoccidioidomycosis with a single brainstem lesion. A case report and literature review. Neuroradiol J (2010) 23(4):454–8.10.1177/197140091002300416
    1. Barkovich AJ, Krischer J, Kun LE, Packer R, Zimmerman RA, Freeman CR, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg (1990–1991) 16(2):73–83.
    1. Fischbein NJ, Prados MD, Wara W, Russon C, Edwards MS, Barkovich AJ. Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg (1996) 24(1):9–23.10.1159/000121010
    1. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol (2006) 24:1266–72.10.1200/JCO.2005.04.6599
    1. Hankinson TC, Campagna EJ, Foreman NK, Handler MH. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons. J Neurosurg Pediatr (2011) 8:97–102.10.3171/2011.4.PEDS1180
    1. Kieran MW. Time to rethink the unthinkable: upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Pediatr Blood Cancer (2015) 62:3–4.10.1002/pbc.25266
    1. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet (2014) 46(5):462–6.10.1038/ng.2950
    1. Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, et al. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol (2014) 128(5):743–53.10.1007/s00401-014-1338-3
    1. Bechet D, Gielen GGH, Korshunov A, Pfister SM, Rousso C, Faury D, et al. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol (2014) 128(5):733–41.10.1007/s00401-014-1337-4
    1. Khuong-Quang D, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 124:439–47.10.1007/s00401-012-0998-0
    1. Buczkowicz P, Hoeman C, Rakopoulus P, Pajovic S, Letourneau L, Dzamba M, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet (2014) 46(5):451–6.10.1038/ng.2936
    1. Mantravadi RV, Phatak R, Bellur S, Liebner EJ, Hass R. Brain stem gliomas: an autopsy study of 25 cases. Cancer (1982) 49(6):1294–6.10.1002/1097-0142(19820315)49:6<1294::AID-CNCR2820490636>;2-V
    1. Halperin EC. Pediatric brain stem tumors: patterns of treatment failure and their implications for radiotherapy. Int J Radiat Oncol Biol Phys (1985) 11(7):1293–8.10.1016/0360-3016(85)90244-5
    1. Freeman CR, Krischer JP, Sanford A, Cohen ME, Burger PC, Carpio RD, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a pediatric oncology group study. Int J Radiat Oncol Biol Phys (1993) 27(2):197–206.10.1016/0360-3016(93)90228-N
    1. Donahue B, Allen J, Siffert J, Rosovsky M, Pinto R. Patterns of recurrence in brain stem gliomas: evidence for cranio-spinal dissemination. Int J Radiat Oncol Biol Phys (1998) 40(3):677–80.10.1016/S0360-3016(97)00846-8
    1. Yoshimura J, Onda K, Tanaka R, Takahashi H. Clinico-pathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir (Tokyo) (2003) 43:375–82.10.2176/nmc.43.375
    1. Benesch M, Wagner S, Berthold F, Wolff JEA. Primary dissemination of high-grade gliomas in children: experiences from four studies of the pediatric oncology and hematology society of the german language group (GPOH). J Neurooncol (2005) 72:179–83.10.1007/s11060-004-3546-5
    1. Wagner S, Benesch M, Berthold F, Gnekow AK, Rutkowski S, Strater R, et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer (2006) 95:991–7.10.1038/sj.bjc.6603402
    1. Gururangan S, McLaughlin CA, Brashears J, Watral MA, Provenzale J, Coleman E, et al. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol (2006) 77:207–12.10.1007/s11060-005-9029-5
    1. Sethi R, Allen J, Donahue B, Karajannis M, Gardner S, Wisoff J, et al. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol (2011) 102:121–7.10.1007/s11060-010-0301-y
    1. Caretti V, Jansen MHA, van Vuurden DG, Lagerweij R, Bugiani M, Horsman I, et al. Implementation of a multi-institutional diffuse intrinsic pontine glioma autopsy protocol and characterization of a primary cell culture. Neuropathol Appl Neurobiol (2013) 39:426–36.10.1111/j.1365-2990.2012.01294.x
    1. Caretti V, Bugiani M, Freret M, Schellen P, Jansen M, van Vuurden DG, et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol (2014) 128(4):605–7.10.1007/s00401-014-1307-x
    1. Vanan MI, Eisenstat DD. Management of high grade gliomas in the pediatric patient: (past), present and the future. Neurooncol Pract (2014) 1(4):145–57.10.1093/nop/npu022
    1. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sub lethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res (2001) 61(6):2744–50.
    1. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M, et al. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol (2006) 76:227–37.10.1007/s11060-005-6499-4
    1. Park MC, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res (2006) 66(17):8511–9.10.1158/0008-5472.CAN-05-4340
    1. Vanan I, Dong Z, Tosti E, Warshaw G, Symons M, Ruggieri R. Role of DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion. Cell Mol Neurobiol (2012) 32:1199–208.10.1007/s10571-012-9846-y
    1. Cockle JV, Picton S, Levesley J, Ilett E, Carcaboso AM, Short S, et al. Cell migration in pediatric glioma; characterization and potential therapeutic targeting. Br J Cancer (2015) 112(4):693–703.10.1038/bjc.2015.16
    1. Muller K, Schlamann A, Guckenberger M, Warmuth-Metz M, Gluck A, Pietschmann S, et al. Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. Strahlenther Onkol (2014) 190:377–81.10.1007/s00066-013-0513-0
    1. Slavc I, Schuller E, Falger G, Gunes M, Pillwein K, Czech T, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n=26) and etoposide (n=11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol (2003) 64(3):239–47.10.1023/A:1025633704071
    1. Jenkin RDT, Boesel C, Ertel I, Evans A, Hittle R, Ortega J, et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR and prednisone. A report of the childrens cancer group study. J Neurosurg (1987) 66(2):227–33.10.3171/jns.1987.66.2.0227
    1. Packer RJ, Littman PA, Sposto RM, D’Angio G, Priest JR, Heideman RL, et al. Results of a pilot study of hyper-fractionated radiation therapy for children with brain stem gliomas. Int J Radiat Oncol Biol Phys (1987) 13:1647–51.10.1016/0360-3016(87)90160-X
    1. Freeman CR, Krischer J, Sanford RA, Burger PC, Cohen M, Norris D, et al. Hyper-fractionated radiotherapy in brain stem tumors: results of a pediatric oncology group study. Int J Radiat Oncol Biol Phys (1988) 15(2):311–8.10.1016/S0360-3016(98)90010-4
    1. Edwards MSB, Wara WM, Urtasun RC, Prados M, Levin VA, Fulton D, et al. Hyper-fractionated radiation therapy for brain-stem glioma: a phase I-II trial. J Neurosurg (1989) 70(5):691–700.10.3171/jns.1989.70.5.0691
    1. Freeman CR, Krischer J, Sanford RA, Cohen M, Burger PC, Kun L, et al. Hyper-fractionated radiation therapy in brain stem tumors: results of treatment at the 7020 cGy dose level of pediatric oncology group study #8495. Cancer (1991) 68:474–81.10.1002/1097-0142(19910801)68:3<474::AID-CNCR2820680305>;2-7
    1. Packer RJ, Boyett JM, Zimmerman RA, Rorke LB, Kaplan AM, Albright AL, et al. Hyper-fractionated radiation therapy (72Gy) for children with brain stem gliomas. Cancer (1993) 72:1414–21.10.1002/1097-0142(19930815)72:4<1414::AID-CNCR2820720442>;2-C
    1. Packer RJ, Boyett JM, Zimmerman RA, Albright AL, Kaplan AM, Rorke LB, et al. Outcome of children with brain stem gliomas after treatment with 7800cGy of hyper-fractionated radiotherapy. Cancer (1994) 74:1827–34.10.1002/1097-0142(19940915)74:6<1827::AID-CNCR2820740628>;2-Q
    1. Packer RJ, Prados M, Phillips P, Nicholson HS, Boyett JM, Goldwein J, et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyper-fractionated radiation therapy. Cancer (1996) 77(10):2150–6.10.1002/(SICI)1097-0142(19960515)77:10<2150::AID-CNCR28>;2-T
    1. Lewis J, Lucraft H, Gholkar A. UKCCSG study of accelerated radiotherapy for pediatric brain stem gliomas. Int J Radiat Oncol Biol Phys (1997) 38(5):925–9.10.1016/S0360-3016(97)00134-X
    1. Janssens GRJ, Gidding CEM, Van Lindert EJ, Oldenburger FR, Erasmus CE, Schouten-Meeteren AYN, et al. The role of hypo-fractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int J Radiat Oncol Biol Phys (2009) 73(3):722–6.10.1016/j.ijrobp.2008.05.030
    1. Negretti L, Bouchireb K, Levy-Piedbois C, Habrand JL, Dhermain F, Kalifa C, et al. Hypo-fractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution’s experience. J Neurooncol (2011) 104:773–7.10.1007/s11060-011-0542-4
    1. Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and re-irradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys (2008) 71(1):87–97.10.1016/j.ijrobp.2007.09.037
    1. Bouffet E, Hawkins CE, Ballourah W, Taylor MD, Bartels UK, Schoenhoff N, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with re-irradiation. Int J Radiat Oncol Biol Phys (2012) 83(5):1541–8.10.1016/j.ijrobp.2011.10.039
    1. Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, et al. Palliative re-irradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol (2012) 35:51–7.10.1007/s00381-013-2350-y
    1. Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse intrinsic pontine glioma. J Neurooncol (2014) 118:305–12.10.1007/s11060-014-1428-z
    1. Khatua S, Hou P, Bodiwala R, Wolff J, Hamilton J, Patil S, et al. Preliminary experience with diffusion tensor imaging before and after re-irradiation treatments in children with progressive diffuse pontine glioma. Childs Nerv Syst (2014) 30:925–30.10.1007/s00381-013-2350-y
    1. Lassaletta A, Bartels U, Strother D, Issaivanan M, Ku D, Laperriere N, et al. ­Re-Irradiation in patients with Diffuse Intrinsic Pontine Gliomas–The Canadian Experience. Poster Presentation-SIOP 2015, Cape Town, South Africa: (2015).
    1. Kretschmar CS, Tarbell NJ, Barnes PD, Krischer JP, Burger PC, Kun L. Pre-irradiation chemotherapy and hyper-fractionated radiation therapy (66 Gy) for children with brain stem tumors. A phase II study of the pediatric oncology group, protocol 8833. Cancer (1993) 72(4):1404–13.10.1002/1097-0142(19930815)72:4<1404::AID-CNCR2820720441>;2-G
    1. Dunkel IJ, Garvin JH, Goldman S, Ettinger LJ, Kaplan AM, Cairo M, et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. children’s cancer group. J Neurooncol (1998) 37(1):67–73.10.1023/A:1005874508975
    1. Jakacki RI, Siffert J, Jamison C, Velasquez L, Allen JC. Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas. J Neurooncol (1999) 44(1):77–83.10.1023/A:1006360222643
    1. Jennings MT, Sposto R, Boyett JM, Vezina LG, Holmes E, Berger MS, et al. Pre-radiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the children’s cancer group. J Clin Oncol (2002) 20(16):3431–7.10.1200/JCO.2002.04.109
    1. Doz F, Neuenschwander S, Bouffet E, Gentet JC, Schneider P, Kalifa C, et al. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Socie´te´ Franc¸aise d’Oncologie Pe´diatrique. Eur J Cancer (2002) 38:815–9.10.1016/S0959-8049(02)00029-1
    1. Grundy RG, Wilne SH, Robinson KJ, Ironside JW, Cox T, Chong WK, et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer (2010) 46(1):120–33.10.1016/j.ejca.2009.09.013
    1. Frappaz D, Schell M, Thiesse P, Marec-Berard P, Mottolese C, Bergeron C, et al. Pre-radiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol (2008) 10(4):599–607.10.1215/15228517-2008-029
    1. Massimino M, Spreafico F, Biassoni V, Simonetti F, Riva D, Trecate G, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol (2008) 87:355–61.10.1007/s11060-008-9525-5
    1. Wolff JE, Kortmann RD, Wolff B, Pietsch T, Peters O, Schmid HJ, et al. High dose methotrexate for pediatric high grade glioma-results of the HIT-GBM-D pilot study. J Neurooncol (2011) 102:433–42.10.1007/s11060-010-0334-2
    1. Levin VA, Edwards MS, Wara WM, Allen J, Ortega J, Vestnys P. 5-Fluorouracil and CCNU followed by hydroxyurea, misonidazole and irradiation for brain stem gliomas: a pilot study of the brain tumor research center and the childrens cancer group. Neurosurgery (1984) 14(6):679–81.10.1227/00006123-198406000-00006
    1. Wakabayashi T, Yoshida J, Mizuno M, Kito A, Sugita K. Effectiveness of interferon–B, ACNU and radiation therapy in pediatric patients with brainstem glioma. Neurol Med Chir (Tokyo) (1992) 32:942–6.10.2176/nmc.32.942
    1. Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T. High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmocol (1997) 39:376–9.10.1007/s002800050586
    1. Walter AW, Gajjar A, Ochs JS, Langston JW, Sanford RA, Kun LE, et al. Carboplatin and etoposide with hyper-fractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. Med Pediatr Oncol (1998) 30:28–33.10.1002/(SICI)1096-911X(199801)30:1<28::AID-MPO9>;2-2
    1. Allen J, Siffert J, Donahue B, Nirenberg A, Jakacki R, Robertson P, et al. A phase I/II study of carboplatin combined with hyper-fractionated radiotherapy for brainstem gliomas. Cancer (1999) 86:1064–9.10.1002/(SICI)1097-0142(19990915)86:6<1064::AID-CNCR24>;2-1
    1. Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, et al. There is no role for hyper-fractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a pediatric oncology group phase III trial comparing conventional vs. hyper-fractionated radiotherapy. Int J Radiat Oncol Biol Phys (1999) 43(5):959–64.10.1016/S0360-3016(98)00501-X
    1. Freeman CR, Kepner J, Kun LE, Sanford RA, Kadota R, Mandell L, et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys (2000) 47(3):561–4.10.1016/S0360-3016(00)00471-5
    1. Bouffet E, Raquin M, Doz F, Gentet JC, Rodary C, Demeocq F, et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer (2000) 88:685–92.10.1002/(SICI)1097-0142(20000201)88:3<685::AID-CNCR27>;2-K
    1. Broniscer A, da Costa Leite C, Lanchote VL, Machado TMS, Cristofani LM. Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. J Clin Oncol (2000) 18(6):1246–53.
    1. Wolff JE, Westphal S, Molenkamp G, Gnekow A, Warmuth-Metz M, Rating D, et al. Treatment of pediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer (2002) 87:945–9.10.1038/sj.bjc.6600552
    1. Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goumnerova L, et al. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys (2003) 55(5):1182–5.10.1016/S0360-3016(02)04391-2
    1. Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the children’s cancer group-0952. Neuro Oncol (2003) 5(1):8–13.10.1093/neuonc/5.1.8
    1. Bernier-Chastagner V, Grill J, Doz F, Bracard S, Gentet JC, Marie-Cardine A, et al. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French society of paediatric oncology phase II study. Cancer (2005) 104:2792–7.10.1002/cncr.21534
    1. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, et al. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer (2005) 104:1281–7.10.1002/cncr.21301
    1. Greenberg ML, Fisher PG, Freeman C, Korones DN, Bernstein M, Friedman H, et al. Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatr Blood Cancer (2005) 45(5):644–8.10.1002/pbc.20382
    1. Wolff JE, Wagner S, Reinert C, Gnekow A, Kortmann RD, Kuhl J, et al. Maintenance treatment with interferon-gamma and low dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol (2006) 79(3):315–21.10.1007/s11060-006-9147-8
    1. Warren K, Jakacki RI, Widemann B, Aikin A, Libucha M, Packer RJ, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the children’s oncology group. Cancer Chemother Pharmacol (2006) 58:343–7.10.1007/s00280-005-0172-7
    1. Turner CD, Chi S, Marcus KJ, MacDonald T, Packer RJ, Poussaint TY, et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol (2007) 82:95–101.10.1007/s11060-006-9251-9
    1. Korones DN, Fisher PG, Kretschmar C, Zhou T, Chen Z, Kepner J, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a children’s oncology group phase II study. Pediatr Blood Cancer (2008) 50(2):227–30.10.1002/pbc.21154
    1. Michalski A, Bouffet E, Taylor RE, Hargrave D, Walker D, Picton S, et al. The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol (2010) 100(1):81–8.10.1007/s11060-010-0141-9
    1. Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, Rutkowski S, Pietsch T, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer (2010) 116(3):705–12.10.1002/cncr.24730
    1. Cohen K, Heideman R, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the children’s oncology group. Neuro Oncol (2011) 4:410–6.10.1093/neuonc/noq205
    1. Chassot A, Canale S, Varlet P, Puget S, Roujeau T, Negretti L, et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol (2012) 106:399–407.10.1007/s11060-011-0681-7
    1. Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom children’s cancer study group and French society for pediatric oncology intergroup study. J Clin Oncol (2002) 20:4684–91.10.1200/JCO.2002.08.141
    1. Broniscer A, Iacono L, Chintagumpala M, Fouladi M, Wallace D, Bowers DC, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. Cancer (2005) 103:133–9.10.1002/cncr.20741
    1. Sirachainan N, Pakakasama S, Visudithbhan A, Chiamchanya S, Tuntiyatorn L, Dhanachai M, et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol (2008) 10:577–82.10.1215/15228517-2008-025
    1. Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys (2010) 77:113–8.10.1016/j.ijrobp.2009.04.031
    1. Chiang KL, Chang KP, Lee YY, Huang PI, Hsu TR, Chen YW, et al. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. Childs Nerv Syst (2010) 26:1035–41.10.1007/s00381-010-1106-1
    1. Kim CY, Kim SK, Phi JH, Lee MM, Kim IA, Kim IH, et al. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean society for pediatric neuro-oncology study. J Neurooncol (2010) 100:193–8.10.1007/s11060-010-0157-1
    1. Sharp JR, Bouffet E, Stempak D, Gammon J, Stephens D, Johnston DL, et al. A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed pediatric brainstem glioma. Eur J Cancer (2010) 46:3271–9.10.1016/j.ejca.2010.06.115
    1. Kebudi R, Cakir FB, Yaman Agaoglu F, Gorgun O, Ayan I, Darendeliler E. Pediatric diffuse intrinsic pontine glioma patients from a single center. Childs Nerv Syst (2013) 29(4):583–8.10.1007/s00381-012-1986-3
    1. Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – results of a United Kingdom phase II trial (CNS-2007-04). Eur J Cancer (2013) 49:3856–62.10.1016/j.ejca.2013.08.006
    1. Zaky W, Wellner M, Brown RJ, Bluml S, Finlay JL, Dhall G. Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan and bevacizumab. Pediatr Hematol Oncol (2013) 30(7):623–32.10.3109/08880018.2013.829895
    1. Aguilera DG, Mazewski C, Hayes L, Jordan C, Esiashivilli N, Janns A, et al. Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolomide and bevacizumab: report of 2 cases. J Pediatr Hematol Oncol (2013) 35(1):e42–6.10.1097/MPH.0b013e318279aed8
    1. Rizzo D, Scalzone M, Ruggiero A, Maurizi P, Attina G, Mastrangelo S, et al. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J Chemother (2015) 27(2):106–10.10.1179/1973947814Y.0000000228
    1. Warren KE. Diffuse intrinsic pontine glioma: poised for progress. Front Oncol (2012) 2:205.10.3389/fonc.2012.00205
    1. Veringa SJE, Biesmans D, van Vuurden DG, Jansen MHA, Wedekind LE, Horsman I, et al. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One (2013) 8(4):e61512.10.1371/journal.pone.0061512
    1. Siegal T. Which drug or drug delivery system can change clinical practice for brian tumor therapy? Neuro Oncol (2013) 15(6):656–69.10.1093/neuonc/not016
    1. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev (2004) 30:415–23.10.1016/j.ctrv.2004.04.001
    1. Siegal T, Rubinstein R, Bokstein F, Schwartz A, Lossos A, Shalom E, et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg (2000) 92:599–605.10.3171/jns.2000.92.4.0599
    1. Prados MD, Schold SC, Fine HA, Jaeckle K, Hochberg F, Mechtler L, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol (2003) 5:96–103.10.1093/neuonc/5.2.96
    1. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters-present status and challenges. Expert Opin Drug Metab Toxicol (2008) 4(2):205–23.10.1517/17425255.4.2.205
    1. Jones C, Perryman L, Hargrave D. Paediatric and adult malignant glioma: close relatives or distant cousins. Nat Rev Clin Oncol (2012) 9:400–13.10.1038/nrclinonc.2012.87
    1. Jansen MHA, van Vuurden DG, Vandertop WP, Kaspers GJL. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev (2012) 38:27–35.10.1016/j.ctrv.2011.06.007
    1. Kebudi R, Cakir FB. Management of diffuse pontine gliomas in children: recent developments. Pediatr Drugs (2013) 15:351–62.10.1007/s40272-013-0033-5
    1. Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, et al. ITCC (innovative therapies for children with cancer) European consortium. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol (2011) 13(1):109–18.10.1093/neuonc/noq141
    1. Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the pediatric brain tumor consortium. Neuro Oncol (2011) 13(3):290–7.10.1093/neuonc/noq199
    1. Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer (2010) 46(18):3287–93.10.1016/j.ejca.2010.07.005
    1. Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric intrinsic pontine gliomas. Expert Opin Biol Ther (2011) 11(2):247–56.10.1517/14712598.2011.546341
    1. Bartels U, Wolff J, Gore L, Dunkel I, Gilheeney S, Allen J, et al. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol (2014) 16(11):1554–9.10.1093/neuonc/nou091
    1. Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol (2010) 28(31):4762–8.10.1200/JCO.2010.30.3545
    1. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a pediatric brain tumor consortium report. Neuro Oncol (2007) 9:145–60.10.1215/15228517-2006-031
    1. Gururangan S, Chi SN, Poussaint TY, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J Clin Oncol (2010) 28:3069–75.10.1200/JCO.2009.26.8789
    1. Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol (2010) 12:985–90.10.1093/neuonc/noq033
    1. Salloum R, DeWire M, Lane A, Goldman S, Hummel T, Chow L, et al. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with bevacizumab-based therapy at diagnosis. J Neurooncol (2015) 121:591–8.10.1007/s11060-014-1671-3
    1. Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M, et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer (2012) 48:253–62.10.1016/j.ejca.2011.09.021
    1. Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol (2011) 13(3):298–306.10.1093/neuonc/noq202
    1. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J Clin Oncol (2008) 26:919–24.10.1200/JCO.2007.14.1812
    1. Felix FHC, de Araujo OL, da Trindade KM, Trompieri NM, Fontenele BJ. Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center. J Neurooncol (2014) 116:261–6.10.1007/s11060-013-1280-6
    1. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med (2015) 21(7):827.10.1038/nm0715-827a
    1. Li G, Mitra SS, Monje M, Henrich KN, Bangs CD, Nitta RT, et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol (2012) 108:395–402.10.1007/s11060-012-0842-3
    1. Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH, et al. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol (2013) 111:257–64.10.1007/s11060-012-1021-2
    1. Pollack IJ, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol (2014) 32:2050–8.10.1200/JCO.2013.54.0526
    1. Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Stewart S, et al. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer (2013) 60:1397–401.10.1002/pbc.24562
    1. Hipp S, Steffen-Smith E, Hammoud D, Shih J, Bent R, Warren K. Predicting outcome of children with diffuse intrinsic pontine gliomas using multi-parametric imaging. Neuro Oncol (2011) 13:904–9.10.1093/neuonc/nor076
    1. Steffen-Smith EA, Venzon DJ, Bent RS, Hipp SJ, Warren KE. Single- and multivoxel proton spectroscopy in pediatric patients with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys (2012) 84(3):774–9.10.1016/j.ijrobp.2012.01.032
    1. Jansen MH, van Zanten SEV, Aliaga ES, Heymans MW, Warmuth-Metz M, Hargrave D, et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol (2015) 17(1):160–6.10.1093/neuonc/nou104
    1. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med (2014) 20(12):1394–6.10.1038/nm.3716
    1. Funato K, Major T, Lewis PW, David Allis C, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science (2014) 346(6216):1529–33.10.1126/science.1253799
    1. Aoki Y, Hashizume R, Ozawa T, Banerjee A, Prados M, David James C, et al. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. J Neurooncol (2012) 108:29–35.10.1007/s11060-011-0796-x
    1. Saratsis AM, Kambhampati M, Snyder K, Yadavilli S, Devany JM, Harmon B, et al. Comparative multi-dimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol (2014) 127:881–95.10.1007/s00401-013-1218-2

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe